Hims & Hers Health (NYSE:HIMS) Given New $20.00 Price Target at TD Cowen

Hims & Hers Health (NYSE:HIMS) had its price objective reduced by TD Cowen from $30.00 to $20.00 in a research note released on Monday morning,Benzinga reports. TD Cowen currently has a hold rating on the stock.

A number of other research analysts have also recently commented on the company. Bank of America decreased their price target on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating on the stock in a research note on Monday. Leerink Partners raised Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. Evercore started coverage on Hims & Hers Health in a report on Monday, January 12th. They set an “in-line” rating and a $33.00 target price for the company. Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Finally, Barclays began coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $39.96.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $19.33 on Monday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a market cap of $4.40 billion, a P/E ratio of 35.80, a P/E/G ratio of 3.79 and a beta of 2.43. The firm’s 50 day moving average price is $32.60 and its 200-day moving average price is $43.05. Hims & Hers Health has a one year low of $16.35 and a one year high of $72.98.

Hims & Hers Health declared that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Insider Activity

In related news, insider Deborah M. Autor sold 7,054 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. This represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 129,337 shares of company stock valued at $4,651,648. 17.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $26,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health during the second quarter worth approximately $29,000. Finally, Bessemer Group Inc. lifted its stake in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Some investors and analysts argue the market has overreacted: HIMS is not a pure GLP‑1 company, management says the oral Wegovy was pulled, and estimates (e.g., ~30% of 2025 revenue from weight‑loss) imply the business still has diversified exposure to preventative care and platform growth. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Hims announced it will stop offering the compounded semaglutide pill after the FDA signaled tighter control over compounded GLP‑1 ingredients — this removes a near‑term revenue initiative but also reduces ongoing regulatory exposure from that specific product. Hims & Hers drops plan for knockoff of Novo Nordisk’s new Wegovy weight loss pill
• Negative Sentiment: Novo Nordisk filed a patent‑infringement lawsuit seeking to block HIMS from selling compounded versions of semaglutide and to recover damages — this escalates legal risk and could lead to injunctions or settlement costs. Novo Nordisk sues Hims & Hers over patent infringement
• Negative Sentiment: Investor reaction has been severe: shares plunged with heavy volume to new lows, prompting multiple analyst cuts (Citigroup, TD Cowen, BofA) that trimmed price targets and ratings — increasing near‑term downside pressure. Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
• Negative Sentiment: Plaintiff and securities firms have opened inquiries and investor lawsuits/claims are being solicited, adding potential legal and reputational costs. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.